Can hyperinsulinemia and insulin resistance contribute to benign prostatic hyperplasia?

At age 77, BPH/LUTS commonly reflects both prostate growth and a dynamic smooth-muscle component of obstruction. The proposed metabolic pathways are biologically credible, but their evidentiary strength differs: local IGF signaling is best supported, whereas links from systemic insulin resistance to prostatic disease remain indirect.

Growth-signaling evidence

• Human BPH tissue and patient-derived organoids support a stromal IGF1→epithelial IGF1R pathway. Fibroblast-derived IGF1 activates epithelial IGF1R/IRS-1, Akt and MAPK signaling, increases cyclin D, lowers p27, and promotes proliferation; IGF1 is required for BPH-organoid growth.
• Hyperinsulinemia could augment this biology through insulin/IGF1R cross-activation. Observational data link metabolic syndrome to modestly larger prostate volume, and one cohort associated higher fasting insulin with faster growth. However, other adjusted community analyses found no association of fasting insulin or HOMA-IR with BPH outcomes, and HOMA-IR did not independently predict LUTS progression in REDUCE.

Sympathetic and symptom mechanisms

• Euglycemic insulin-clamp studies show that insulin acutely raises muscle sympathetic nerve activity and plasma norepinephrine, consistent with centrally mediated sympathoexcitation.
• Prostatic α1A-adrenoceptors on smooth muscle mediate noradrenergic contraction and the dynamic component of bladder-outlet resistance. This provides a credible route by which insulin-related adrenergic tone could worsen flow or LUTS; it does not establish that it enlarges the prostate. α1-blocker benefit supports the functional relevance of this pathway.

Inflammation

• NF-κB-associated cytokine activity, including IL-6 and IL-8, can promote stromal and epithelial proliferation. In MTOPS, histologic inflammation occurred in approximately 40% of baseline biopsies and was associated with larger prostate volume, higher PSA, and more progression events; acute urinary retention occurred in 5.6% with inflammation versus 0% without in the placebo group.
• A direct human link from measured hyperinsulinemia/insulin resistance to intraprostatic inflammation has not been demonstrated.

Bottom line

• Hyperinsulinemia and insulin resistance are plausible contributors to BPH biology—most convincingly through local IGF-driven growth and potentially through adrenergic symptom amplification and inflammation—but they are not established independent causes of BPH progression in humans.